

Svetlana A Ivanova

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/994676/svetlana-a-ivanova-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

1,160
citations

18
h-index

28
g-index

172
ext. papers

1,581
ext. citations

2.7
avg, IF

4.92
L-index

#	Paper	IF	Citations
126	Molecular genetic study of clinical and cognitive features of schizophrenia: No associations with genes SOD2, GSTO1, NQO1. <i>Sibirskij žurnal Kliničkoj i Eksperimental'noj Mediciny</i> , 2022 , 36, 99-106	0.3	0
125	Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 880568	5	6
124	Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome. <i>Genes</i> , 2022 , 13, 844	4.2	0
123	Circuits Regulating Pleasure and Happiness - Focus on Potential Biomarkers for Circuitry including the Habenuloid Complex.. <i>Acta Neuropsychiatrica</i> , 2022 , 1-36	3.9	3
122	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. <i>Human Psychopharmacology</i> , 2021 , e2826	2.3	1
121	Assessment of serum BDNF levels in complex rehabilitation of patients with ischemic stroke using traditional approaches to the restoration of motor functions. <i>Bulletin of Siberian Medicine</i> , 2021 , 20, 38-45	0.4	0
120	Rare single nucleotide variants in COL5A1 promoter do not play a major role in keratoconus susceptibility associated with rs1536482. <i>BMC Ophthalmology</i> , 2021 , 21, 357	2.3	1
119	Genetic Polymorphisms of Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
118	Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	6
117	Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness. <i>Psychiatry</i> , 2021 , 19, 39-45	0.4	1
116	Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction. <i>Translational Psychiatry</i> , 2021 , 11, 365	8.6	5
115	Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. <i>Journal of Psychopharmacology</i> , 2021 , 35, 3-14	4.6	5
114	A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 105, 110134	5.5	2
113	Peripheral Markers of Nervous Tissue Damage in Addictive and Affective Disorders. <i>Neurochemical Journal</i> , 2021 , 15, 86-90	0.5	0
112	Features of brain activity in alcohol dependence in the task of inhibitory control. <i>Bulletin of Siberian Medicine</i> , 2021 , 19, 38-45	0.4	3
111	Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study. <i>Metabolites</i> , 2021 , 11,	5.6	1
110	Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1

109	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. <i>Frontiers in Psychiatry</i> , 2021 , 12, 661174	5	3
108	Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
107	Search for Possible Associations of Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021 , 14, 1123-1131	2.1	1
106	Metabolic Syndrome in a Population of In-Patients with Schizophrenia in the Western Siberia. <i>Psychiatry</i> , 2021 , 19, 52-60	0.4	
105	A New Paradigm to Indicate Antidepressant Treatments.. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
104	Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
103	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. <i>Frontiers in Molecular Neuroscience</i> , 2020 , 13, 63	6.1	6
102	Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression. <i>Frontiers in Psychiatry</i> , 2020 , 11, 296	5	9
101	Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia. <i>The Application of Clinical Genetics</i> , 2020 , 13, 97-105	3.1	2
100	Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia. <i>Human Psychopharmacology</i> , 2020 , 35, e2737	2.3	1
99	Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1827-1835	3.8	6
98	Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients. <i>Frontiers in Psychiatry</i> , 2020 , 11, 38	5	7
97	IgG-Dependent Dismutation of Superoxide in Patients with Different Types of Multiple Sclerosis and Healthy Subjects. <i>Oxidative Medicine and Cellular Longevity</i> , 2020 , 2020, 8171020	6.7	5
96	Relationship of cognitive disorders with clinical features of alcohol dependence. <i>Русский Медицинский Журнал</i> , 2020 , 62-65	0.2	
95	Glutamate Levels in Blood Serum of Patients with Schizophrenic Spectrum and Bipolar Affective Disorder. <i>Psychiatry</i> , 2020 , 18, 22-31	0.4	2
94	Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy. <i>Bulletin of Siberian Medicine</i> , 2020 , 18, 197-208	0.4	2
93	Clinical and laboratory assessment of the effectiveness of early rehabilitation of patients with stroke using assistive robotic tools. <i>Bulletin of Siberian Medicine</i> , 2020 , 18, 55-62	0.4	1
92	Cognitive Changes in Comorbidity Alcohol Dependence and Affective Disorders. <i>Psychiatry</i> , 2020 , 18, 42-48	0.4	0

91	Using the quantitative EEG method in predicting the response to treatment of affective disorders. <i>VM Bekhterev Review of Psychiatry and Medical Psychology</i> , 2020 , 26-32	0.4	1
90	Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 325-329	3.2	3
89	Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia. <i>Journal of Immunology Research</i> , 2020 , 2020, 8986521	4.5	6
88	Serum BDNF's Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke. <i>Brain Sciences</i> , 2020 , 10,	3.4	9
87	P.568 Trihexyphenidyl in combination with antipsychotic therapy does not affect the severity of neurocognitive deficits in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2020 , 40, S322-S323	1.2	
86	Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia. <i>Metabolites</i> , 2020 , 10,	5.6	6
85	Genetic polymorphisms of PIP5K2A and course of schizophrenia. <i>BMC Medical Genetics</i> , 2020 , 21, 171	2.1	3
84	Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome. <i>Diagnostics</i> , 2020 , 10,	3.8	5
83	,, and as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder. <i>Frontiers in Genetics</i> , 2020 , 11, 936	4.5	2
82	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of and muscarinic receptors. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 72-77	3.8	9
81	Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2020 , 16, 1051-1058	3.1	5
80	Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. <i>Molecular Psychiatry</i> , 2019 , 24, 1099-1111	15.1	7
79	Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD. <i>Pharmacopsychiatry</i> , 2019 , 52, 203-204	2	3
78	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. <i>BMC Medical Genetics</i> , 2019 , 20, 47	2.1	12
77	Autoimmunity and immune system dysregulation in schizophrenia: IgGs from sera of patients hydrolyze myelin basic protein. <i>Journal of Molecular Recognition</i> , 2019 , 32, e2759	2.6	14
76	The difference in serum proteomes in schizophrenia and bipolar disorder. <i>BMC Genomics</i> , 2019 , 20, 535	4.5	18
75	Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. <i>Heliyon</i> , 2019 , 5, e02033	3.6	18
74	Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients. <i>Journal of Affective Disorders</i> , 2019 , 259, 432-439	6.6	4

73	Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. <i>Pharmacogenomics</i> , 2019 , 20, 1199-1223	2.6	9
72	NEUROPHYSIOLOGICAL FEATURES OF PATIENTS WITH DIFFERENT RATES OF ALCOHOL DEPENDENCE DEVELOPMENT. <i>Voprosy Narkologii</i> , 2019 , 31-39	0.1	1
71	Association of Polymorphic Variants of Brain-Derived Neurotrophic Factor Gene (Bdnf Rs6265) and Glutamate Transporter Gene of the Second Type (Slc1a2 Rs4354668) with the Course of Multiple Sclerosis in Patients Living in Tomsk Region. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 14-19	0.4	
70	Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. <i>Bulletin of Siberian Medicine</i> , 2019 , 18, 62-71	0.4	0
69	Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1462	5.6	8
68	Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome. <i>Frontiers in Psychiatry</i> , 2019 , 10, 803	5	13
67	P.876 The effect of atypical antipsychotic therapy on hormonal and biochemical parameters in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2019 , 29, S583-S584	1.2	
66	P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome. <i>European Neuropsychopharmacology</i> , 2019 , 29, S276-S277	1.2	
65	No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia. <i>Human Psychopharmacology</i> , 2019 , 34, e2685	2.3	4
64	Evolution of circuits regulating pleasure and happiness with the habenula in control. <i>CNS Spectrums</i> , 2019 , 24, 233-238	1.8	11
63	Allele Frequencies in Depressed Patients of European Descent in Russia. <i>Frontiers in Genetics</i> , 2018 , 9, 686	4.5	2
62	Hydrolysis by catalytic IgGs of microRNA specific for patients with schizophrenia. <i>IUBMB Life</i> , 2018 , 70, 153-164	4.7	10
61	Circuits regulating pleasure and happiness: evolution and role in mental disorders. <i>Acta Neuropsychiatrica</i> , 2018 , 30, 29-42	3.9	22
60	The functional variant rs334558 of is associated with remission in patients with depressive disorders. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 121-126	2.1	9
59	Blood-Derived RNA- and microRNA-Hydrolyzing IgG Antibodies in Schizophrenia Patients. <i>Biochemistry (Moscow)</i> , 2018 , 83, 507-526	2.9	9
58	Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018 , 21, 340-346	3.4	7
57	Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients. <i>International Journal of Obesity</i> , 2018 , 42, 2036-2046	5.5	8
56	Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy. <i>Bulletin of Siberian Medicine</i> , 2018 , 17, 54-64	0.4	3

55	 2018,			3
54	Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 410-411	1.7		3
53	Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy. <i>Neurochemical Journal</i> , 2018, 12, 366-372	0.5		3
52	The evolutionary old forebrain as site of action to develop new psychotropic drugs. <i>Journal of Psychopharmacology</i> , 2018, 32, 1277-1285	4.6		11
51	Commentary on "A non-reward attractor theory of depression": A proposal to include the habenula connection. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 83, 736-741	9		8
50	Association study of genetic markers of schizophrenia and its cognitive endophenotypes. <i>Russian Journal of Genetics</i> , 2017, 53, 139-146	0.6		7
49	The role of the habenula in the transition from reward to misery in substance use and mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 80, 276-285	9		44
48	Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders. <i>Neurochemical Journal</i> , 2017, 11, 185-187	0.5		
47	Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia. <i>PLoS ONE</i> , 2017, 12, e0183867	3.7		10
46	Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. <i>Schizophrenia Research</i> , 2017, 182, 110-114	3.6		17
45	Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 239-246	3.8		21
44	IgG antibodies with nuclease activity in serum of patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2017, 27, S633-S634	1.2		
43	Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT _{2C} Receptor Genes with Criminal Behavior in Russian Criminal Offenders. <i>Neuropsychobiology</i> , 2017, 75, 200-210	4		7
42	Circuits Regulating Pleasure and Happiness in Bipolar Disorder. <i>Frontiers in Neural Circuits</i> , 2017, 11, 35	3.5		15
41	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1211-e1218	4.6		18
40	Antipsychotic-induced tardive dyskinesia: The role of glutamatergic system. <i>European Psychiatry</i> , 2016, 33, S97-S97	6		
39	Circuits regulating pleasure and happiness in major depression. <i>Medical Hypotheses</i> , 2016, 87, 14-21	3.8		45
38	An association of AKT1 gene polymorphism with antidepressant treatment response. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 239-42	3.8		13

37	Use of Carnosine for Oxidative Stress Reduction in Different Pathologies. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 2939087	6.7	53
36	Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding. <i>Parkinson's Disease</i> , 2016 , 2016, 6461907	2.6	6
35	Circuits Regulating Pleasure and Happiness-Mechanisms of Depression. <i>Frontiers in Human Neuroscience</i> , 2016 , 10, 571	3.3	38
34	Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates. <i>Frontiers in Neuroscience</i> , 2016 , 10, 539 ^{5.1}		22
33	Circuits Regulating Pleasure and Happiness: A Focus on Addiction, Beyond the Ventral Striatum 2016 ,		5
32	Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions 2016 ,		2
31	Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. <i>SAGE Open Medicine</i> , 2016 , 4, 2050312116643673	2.4	11
30	CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. <i>Bulletin of Experimental Biology and Medicine</i> , 2016 , 160, 687-90	0.8	21
29	Serum levels of neurosteroids in patients with affective disorders. <i>Bulletin of Experimental Biology and Medicine</i> , 2015 , 158, 638-40	0.8	3
28	DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia. <i>Open Biology</i> , 2015 , 5, 150064	7	23
27	Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age. <i>Human Physiology</i> , 2015 , 41, 444-447	0.3	0
26	Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates. <i>Frontiers in Neuroscience</i> , 2015 , 9, 394	5.1	51
25	Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy. <i>Bulletin of Experimental Biology and Medicine</i> , 2015 , 160, 283-5	0.8	8
24	Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 200-5	3.8	15
23	Proteins of the Akt1/GSK-3 β signaling pathway in peripheral blood mononuclear cells of patients with affective disorders. <i>Neurochemical Journal</i> , 2014 , 8, 208-213	0.5	1
22	Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics. <i>Neurochemical Journal</i> , 2014 , 8, 66-70	0.5	9
21	Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 50, 172-7	5.5	9
20	Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 18,	5.8	19

19	Glutamate Concentration in the Serum of Patients with Schizophrenia. <i>Procedia Chemistry</i> , 2014 , 10, 80-85		7
18	Effects of neuroprotector cortixin on the dynamics of neuroendocrine system parameters in patients with organic emotionally labile (asthenic) disorders. <i>Bulletin of Experimental Biology and Medicine</i> , 2013 , 155, 75-7	0.8	1
17	New insights into the mechanism of drug-induced dyskinesia. <i>CNS Spectrums</i> , 2013 , 18, 15-20	1.8	72
16	Conformational stability of leukocyte lactate dehydrogenase in healthy men of different age. <i>Bulletin of Experimental Biology and Medicine</i> , 2012 , 154, 44-6	0.8	1
15	Neurosteroids dehydroepiandrosterone and its sulfate in individuals with personality disorders convicted of serious violent crimes. <i>Bulletin of Experimental Biology and Medicine</i> , 2012 , 154, 89-91	0.8	6
14	Study of the indices of antioxidant defense in mental maladaptation. <i>Human Physiology</i> , 2012 , 38, 543-547		3
13	Effects of dehydroepiandrosterone sulfate on induced apoptosis of lymphocytes in healthy persons. <i>Human Physiology</i> , 2012 , 38, 534-538	0.3	
12	NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. <i>Translational Psychiatry</i> , 2012 , 2, e67	8.6	40
11	No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. <i>Human Psychopharmacology</i> , 2012 , 27, 334-7	2.3	10
10	The correlation between schizophrenia duration and the serum concentration of dehydroepiandrosterone sulfate. <i>Neurochemical Journal</i> , 2011 , 5, 290-293	0.5	2
9	The state of the antioxidant system during therapy of patients with multiple sclerosis. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2011 , 5, 76-80	0.4	3
8	Spontaneous and in vitro induced apoptosis of lymphocytes and neutrophils in patients with alcohol dependence. <i>Bulletin of Experimental Biology and Medicine</i> , 2010 , 149, 246-9	0.8	3
7	Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. <i>Human Psychopharmacology</i> , 2010 , 25, 84-91	2.3	30
6	PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3. <i>Psychopharmacology</i> , 2009 , 206, 429-35	4.7	22
5	Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009 , 33, 475-81	5.5	44
4	Signs of apoptosis of immunocompetent cells in patients with depression. <i>Neuroscience and Behavioral Physiology</i> , 2007 , 37, 527-30	0.3	34
3	Comparative efficiency of Proproten-100 during the therapy of patients with alcoholism in the stage of therapeutic remission. <i>Bulletin of Experimental Biology and Medicine</i> , 2003 , 135 Suppl 7, 171-5	0.8	1
2	Changes in immunological parameters in patients with opium abuse receiving ANAR therapy. <i>Bulletin of Experimental Biology and Medicine</i> , 2003 , 135 Suppl 7, 189-91	0.8	1

1 Antioxidant and Immunotropic Properties of some Lithium Salts. *Journal of Applied Pharmaceutical Science*,086-089 2 6